

呼吸器外科 研究業績(2023年)

総説

1. Optimal surgery for resectable malignant pleural mesothelioma in the setting of multimodality treatment.
Kondo N, Hasegawa S.
Surg Today
NA (online ahead of print)

原著論文

1. Efficacy and safety of nivolumab with ipilimumab for recurrent malignant pleural mesothelioma after primary surgical intervention.
Nakamura A, Hashimoto M, Kondo N, Matsumoto S, Kuroda A, Kuribayashi K, Kijima T, Hasegawa S.
Int J Clin Oncol. 28 (3). 409-415. 2023
Nivolumab with ipilimumab treatment in patients with recurrent MPM after primary surgical treatment may be clinically efficacious, although serious AEs may be frequently observed.
2. FDG-PET/CT findings can determine tumor response and predict for simultaneous integrated boost intensity modulated radiotherapy with volumetric-modulated arc therapy in locally advanced lung cancer patients.
Ikeda J, Kitajima K, Fujiwara M, Suzuki H, Niwa Y, Yoshimura N, Hasegawa S, Yamakado K.
Acta Med Hyogo. 48 (1). 89-101. 2023
The usefulness of FDG-PET/CT findings for the evaluation of response and prognosis prediction in patients with locally advanced lung cancer treated with simultaneous IMRT was evaluated.

3. Prognosis prediction of patients with malignant pleural mesothelioma using conditional variational autoencoder on 3D PET images and clinical data.

Matsuo H, Kitajima K, Kono AK, Kuribayashi K, Kijima T, Hasegawa S, Yamakado K, Murakami T.

Medical Physics. 50 (12). 7548-57. 2023

This study demonstrates the usefulness of the 3D-CCVAE in multimodal deep-learning models learned using a small number of datasets.

4. The IASLC Pleural Mesothelioma Staging Project: Expanded Database to Inform Revisions in the Ninth Edition of the TNM Classification of Pleural Mesothelioma.

Wolf AS, Opitz I, Galateau-Salle F, Hasegawa S, Kindler HL, Pass HI, Rusch VW

J Thorac Oncol. NA (online ahead of print)

The 9th IASLC mesothelioma registry consisted of a total of 3,598 analyzable cases from Europe, Australia, Asia, North America, and South America, with a median age of 71 years (range 18-99), 2,775 (77.1%) of whom were men.

5. Nationwide prospective registry database of patients with newly diagnosed untreated pleural mesothelioma in Japan.

Hasegawa S, Shintani Y, Endo S, Kadokura M, Okumura M, Hattori S, Date H, Yoshino I

Cancer Science. NA (online ahead of print)

Japan's nationwide prospective registry of patients with pleural mesothelioma was conducted.

6. Impact of surgery on disease progression and survival of patients with pleural mesothelioma.
Nakamura A, Hashimoto M, Kuroda A, Matsumoto S, Kondo N, Kijima T, Hasegawa S.
Ann Thorac Surg. NA (online ahead of print)
Overall survival and progression-free survival were significantly better in surgery than in refusal of surgery.
Surgery may improve the survival outcomes of patients with pleural mesothelioma.

7. 悪性胸膜中皮腫に対する外科療法

黒田鮎美、長谷川誠紀

腫瘍内科. 32(6). 638-641. 2023

胸膜中皮腫では、臨床病期 I - IIIA 期で術後に肉眼的完全切除を得られると考えられる症例に対して外科的切除を行うことが推奨される。

学会発表

1. A proposal of a new nomenclature for malignant pleural mesothelioma.
Seiki Hasegawa, Andrea Bille
International Mesothelioma Interest Group 2023 Workshop 2023.6.26 Lille, France
A new nomenclature for malignant pleural mesothelioma was proposed.
2. Surgical Management of Early Pleural Mesothelioma.
Seiki Hasegawa
World Congress for Lung Cancer 2023 Educational session 16 “Early mesothelioma” 2023.9.10 Singapore
Early mesothelioma is a good indication for surgical treatment.

3. PREDICTIVE FACTORS OF POSTOPERATIVE LONG-TERM SURVIVAL IN PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA.

Masaki Hashimoto, Shota Nakamura, Akifumi Nakamura, Toru Nakamichi, Toyofumi Fengsjo Chen-Yoshikawa, Seiki Hasegawa

European Society for Thoracic Surgeons 2023 Oral 2023.6.4 Milano, Italy

Analysis of long-term survivors after mesothelioma surgery revealed predictive factors.

4. SALVAGE SURGERY AFTER IMMUNOTHERAPY FOR UNRESECTABLE MALIGNANT PLEURAL MESOTHELIOMA.

Kyoshiro Takegahara, Masaki Hashimoto, Akihiro Fkukuda, Toru Nakamichi, Akifumi Nakamura, Ayumi Kuroda, Nobuyuki Kondo, Seiki Hasegawa

European Society for Thoracic Surgeons 2023 Poster 2023.6.4 Milano, Italy

Salvage surgery after immunotherapy was feasible in patients with pleural mesothelioma.

5. CLINICAL CHARACTERISTICS OF LONG-TERM SURVIVORS OF MALIGNANT PLEURAL MESOTHELIOMA.

Masaki Hashimoto, Akifumi Nakamura, Toru Nakamichi, Nobuyuki Kondo, Takashi Kijima, Tohru Tsujimura, Seiki Hasegawa

International Mesothelioma Interest Group 2023 Poster 2023.6.26 Lille, France

Analysis of long-term survivors after mesothelioma surgery revealed predictive factors.

6. SALVAGE SURGERY AFTER IMMUNOTHERAPY FOR UNRESECTABLE MALIGNANT PLEURAL MESOTHELIOMA.

Kyoshiro Takegahara, Masaki Hashimoto, Akihiro Fukuda, Toru Nakamichi, Nobuyuki Kondo, Seiki Hasegawa

International Mesothelioma Interest Group 2023 Poster 2023.6.26 Lille, France

Salvage surgery after immunotherapy was feasible in patients with pleural mesothelioma.

7. PATIENTS WHO UNDERGO SURGERY SURVIVE LONGER THAN THOSE WHO REFUSE SURGERY.

A Nakamura, A Fukuda, K Takegahara, T Nakamichi, A Kuroda, M Hashimoto, S Matsumoto, K Kondo, S Hasegawa

World Congress for Lung Cancer 2023 Poster 2023.9.10 Singapore

Patients undergoing surgery for pleural mesothelioma survived longer than who refused surgery.